EGFR and non-small cell lung carcinoma: For example, mutations in phosphoinositide-3-kinase catalytic alpha (PIK3CA), the p110α catalytic subunit of phosphatidylinositol-3-kinase, are found in approximately 4% of NSCLC patients [8] and result in resistance to EGFR TKI.